BCL2L1 and cancer: UBX1325 (Unity Biotechnology, San Franscisco, CA, USA), another specific BCL- XL inhibitor, is also being evaluated in patients with diabetic macular edema widening the scope of this class of agents beyond cancer (NCT04537884, NCT04857996).